¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 1ÀÏÂ÷ : 2021-11-04

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 1ÀÏÂ÷ : 2021-11-04
±³À°ÀÏÀÚ : 2021-11-04
±³À°Àå¼Ò : ¿Â¶óÀÎ LIVE  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑ°¨¿°ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°¨¿°ÇÐȸ
¿¬¶ôó : 02-2055-1441  
À̸ÞÀÏ : ksinfect@ksid.or.kr      
±³À°Á¾·ù : ³»°ú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°úÀÇ»çÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í Á¤È¸¿ø Àü¹®ÀÇ 100,000 Àü°øÀÇ 60,000 Çлý 40,000ºñȸ¿ø Àü¹®ÀÇ 120,000 Àü°øÀÇ 80,000 Çлý 50,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 08:00~08:25 How to treat : MDR/XDR TB  ÇãÀº¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 08:25~08:50 How to answer : Consultations from hematologic malignancy unit  À̵¿°Ç(°¡Å縯ÀÇ´ë) 
±âŸ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 08:50~09:00 Opening remarks  ¹é°æ¶õ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 09:00~09:20 Invasive fungal infection in severe COVID-19 patients  °­Ã¶ÀÎ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 09:20~09:40 Ongoing battle against gram-postive bacteria  Á¤¿ëÇÊ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 09:40~10:00 Current Perspectives of COVID-19-Associated Pulmonary Aspergillosis in Korea: Multi-centered Retrospective Cohort Study Using Clinical Data Warehouse  ÀÌ·¡¼®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 10:00~10:20 Ç÷¾×Åõ¼® ȯÀÚµé°ú °Ç°­ÀÎÀÇ Äڷγª19 ¹é½Å Á¢Á¾¿¡ µû¸¥ ¹æ¾î Ç×ü »ý¼º Â÷ÀÌ ºÐ¼®: a preliminary report  ±èºÀ¿µ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 10:20~10:40 Rifamycins Resistance, rpoB gene mutation, and Clinical Outcome of Staphylococcus Species Isolated from Prosthetic Joint Infection in Korea  ±è¼ö¼º(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 10:40~11:00 Persistent serotype 3 and 19A invasive pneumococcal diseases despite high pneumococcal vaccine uptake: serotype-dependent differences in antimicrobial resistance and genetic diversity  À±Áø±¸(°í·ÁÀÇ´ë) 
È޽Ġ11-04 ·Ôµ¥È£ÅÚ¿ùµå 11:00~11:10 Break  () 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 11:10~12:00 Therapeutic Potential of Bacteriophage and Endolysin  À¯»ó¿­(¼­¿ï´ë) 
È޽Ġ11-04 ·Ôµ¥È£ÅÚ¿ùµå 12:00~12:10 Break  () 
±âŸ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 12:10~12:40 KSID General Assembly  ¹é°æ¶õ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 12:40~13:30 ±¹³» »óȲ¿¡ ÀûÇÕÇÑ Ç×»ýÁ¦ °ü¸®  À±¿µ°æ(°í·ÁÀÇ´ë) 
È޽Ġ11-04 ·Ôµ¥È£ÅÚ¿ùµå 13:30~13:40 Break  () 
±³À°½Ã°£ 11-04  13:40~13:50 Risk Factors and Microbiological Features of Recurrent Escherichia coli Bloodstream infection  ±è¿ëÂù(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 13:50~14:00 Risk factor-based analysis of healthcare-associated pneumonia: microbiological distribution, antibiotic resistance and clinical outcomes  ÇöÇÐÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:00~14:10 Clinical presentation and impact of carbapenem-resistant Enterobacteriaceae acquisition in patients with hematologic malignancies  À̱âÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:10~14:20 Active surveillance of Clostridioides difficile infections in 10 tertiary hospitals  ±èÁöÀº(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:20~14:30 Serum Irisin levels are decreased in septic patients, and irisin suppresses pro-inflammatory cytokines in mice  ÀüÁöÈÆ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:30~14:40 Gut microbiome in chronic HBV infection is associated with a reduced triglyceride level: An experimental mouse model  ±èº¸¹Ì(°­ºÏ»ï¼ºº´¿ø) 
È޽Ġ11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:40~14:50 Break  () 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:50~15:00 Predictive laboratory parameters of dynamic changes in viral load in patients with severe fever with thrombocytopenia syndrome  ±è¹Ì¼±(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:00~15:10 Safety and immunogenicity of recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike/nucleocapsid proteins: two open-label, phase 1 trials in healthy adults  ¾ÈÁø¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:10~15:20 Whole genome sequence analysis were useful evidence for transmission route for COVID-19 virus via Cargo ship from Russia to South Korea  À̽ÂÈÆ(Áúº´°ü¸®Ã») 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:20~15:30 Dynamics of COVID-19 infections estimated by Public community mobility in South Korea  À¯´ë¼º(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:30~15:40 Viral RNA kinetics of SARS-CoV-2 in non-hospitalized patients according to symptom duration  ±èº¸¹Ì(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:40~15:50 The interaction between gut microbiome and humoral immunogenicity after COVID-19 vaccination  ¼ºÇý(°í·ÁÀÇ´ë) 
È޽Ġ11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:50~16:00 Break  () 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 16:00~16:30 Experiences of and lessons learned from past pandemics  ±è¿ìÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 16:30~17:00 Problems and lessons in management of COVID-19  Á¤ÀçÈÆ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 17:00~17:30 Changes and Tasks in national infectious diseases response strategy in post COVID-19 pandemic  ÀåÈñâ(±¹¸³º¸°Ç¿¬±¸¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 1ÀÏÂ÷ : 2021-11-04""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇǺΰúÇÐȸ ´ë±¸°æºÏÁöºÎ Á¦ 251Â÷ ÇмúÁý´ãȸ: 2021-11-04
´ÙÀ½±Û (¿Â¶óÀÎ) Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ (2ÀÏÂ÷) : 2021-11-04
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21009 ºÎ»ê ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ºÎ»ê°æ³²Áöȸ Çмúȸ : 2024-06-25 0 4 2024-06-17
21008 °æ³² â¿ø½Ã ¼Ò¾Æû¼Ò³â°úÁöȸ ¿¬¼ö°­ÁÂ(¼Ò¾Æ ¼ÒÈ­±â Áúȯ) : 2024-06-25 0 4 2024-06-17
21007 Ãæ³² ´Ü±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ Çмúȸ(±¸°­°ÇÁ¶Áõ) : 2024-06-25 0 4 2024-06-17
21006 ¼­¿ï (¿Â¶óÀÎ) 2024³â 6¿ù ¼Ò¾Æ½ÉÃÊÀ½ÆÄ Áý´ãȸ : 2024-06-24 0 3 2024-06-17
21005 °æ±â 2024³â ¼Ò¾Æ¼ö¸é¿¬±¸È¸ Á¦2Â÷ Áý´ãȸ(¿Â¶óÀÎ) : 2024-06-24 0 2 2024-06-17
21004 Ãæ³² ´Ü±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú (¿Â¶óÀÎ) 29th Vestibular Function Test Workshop : 2024-06-23 0 2 2024-06-17
21003 ¼­¿ï ´ëÇѳëÀο©¼ºÀÇÇÐȸ Á¦33Â÷ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-06-23 0 1 2024-06-17
21002 ¼­¿ï ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦5ȸ ½ÉÈ­ ½ÉÆ÷Áö¾ö : 2024-06-23 0 2 2024-06-17
21001 ºÎ»ê ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ - Á¦19Â÷ Çмú´ëȸ : 2024-06-23 0 2 2024-06-17
21000 ¼­¿ï 2024³â 6¿ù ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 3 2024-06-17
20999 ¼­¿ï Á¦ 10ȸ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ¼­¿ïÁöȸ ¿¬¼ö°­Á : 2024-06-23 0 1 2024-06-17
20998 ¼­¿ï ´ëÇѵÎÅëÇÐȸ 2024³â Ãá°èÇмú´ëȸ : 2024-06-23 0 1 2024-06-17
20997 ´ë±¸ 2024³â ´ëÇѼÒÈ­±âÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö°­Á : 2024-06-23 0 2 2024-06-17
20996 °æ±â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °æÀÎÁöȸ Á¦7ȸ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-23 0 10 2024-06-16
20995 ¼­¿ï Á¦18ȸ ´ëÇѺñ°úÇÐȸ ½ÉÆ÷Áö¾ö : 2024-06-23 0 8 2024-06-16
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷